The standard story about antibiotic resistance is that we need new drugs. But a recent commentary in MedCity News pushes back, arguing that the real bottleneck is not discovery. The molecules already exist; what is missing is a system that can get them to the patients who need them.
That distinction matters. Market entry and access problems—such as pricing, reimbursement, distribution, and regulatory friction—are harder to see than empty pipelines, but they are also more solvable. The piece calls the delivery problem "far more tractable" than the pipeline crisis that dominates public attention.
If the analysis is correct, then the strategy for combating resistant infections should shift. Instead of pouring all effort into hunting for new compounds, policymakers and health systems could focus on removing the barriers that keep existing antibiotics from reaching the bedside. That would not make discovery irrelevant, but it would rebalance priorities toward a fix that is within reach.